{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:24:58Z","timestamp":1783481098708,"version":"3.55.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec id=\"ab-hoi240062-4\"><jats:title>Importance<\/jats:title><jats:p>The clinical utility of polygenic risk scores (PRS) for blood pressure (BP) response to antihypertensive treatment (AHT) has not been elucidated.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240062-5\"><jats:title>Objective<\/jats:title><jats:p>To investigate the ability of a systolic BP (SBP) PRS to predict AHT response and apparent treatment-resistant hypertension (aTRH).<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240062-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Genetics of Hypertension Associated Treatments (GenHAT) study was an ancillary pharmacogenomic study to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT, which enrolled participants aged 55 years or older with hypertension (HTN) starting in February 1994, completed follow-up in March 2002. The current study was conducted from a subset of Black GenHAT participants randomized to the treatment groups of either chlorthalidone (n\u2009=\u20093745) or lisinopril (n\u2009=\u20092294), with genetic data available from a prior genetic association study. The current study's objective was to examine the association of the SBP PRS to AHT response over 6 months, as well as to examine the predictive accuracy of the SBP PRS with aTRH. The current analysis took place in February 2023, with additional analyses conducted in July 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240062-7\"><jats:title>Exposure<\/jats:title><jats:p>An SBP PRS (comprising 1\u202f084\u202f157 genetic variants) stratified as quintiles and per SD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240062-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was change in SBP (\u0394SBP) and diastolic BP (\u0394DBP) over 6 months. aTRH was defined as the use of 3 AHTs with uncontrolled HTN at year 3 of follow-up or taking 4 or more AHTs at year 3 of follow-up, regardless of BP. Baseline demographics were compared across PRS quintiles using Kruskal-Wallis or \u03c7<jats:sup>2<\/jats:sup> tests as appropriate. The least-square means of BP response were calculated through multivariable adjusted linear regression, and multivariable adjusted logistic regression was used to calculate the odds ratios and 95% confidence intervals for aTRH.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240062-9\"><jats:title>Results<\/jats:title><jats:p>Among 3745 Black GenHAT participants randomized to chlorthalidone treatment, median (IQR) participant age was 65 (60-71) years, and 2064 participants (55.1%) were female. Each increasing quintile of the SBP PRS from 1 to 5 was associated with a reduced BP response to treatment over 6 months. Participants in the lowest quintile experienced a mean \u0394SBP of \u221210.01 mm Hg (95% CI, \u221211.11 to \u22128.90) compared to \u22126.57 mm Hg (95% CI, \u22127.67 to \u22125.48) for participants in the median quintile. No associations were observed between the SBP PRS and BP response to lisinopril. Participants in the highest PRS quintile had 67% higher odds of aTRH compared to those in the median quintile (odds ratio, 1.67; 95% CI, 1.19-2.36). These associations were independently validated.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi240062-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this genetic association study, Black individuals with HTN at a lower genetic risk of elevated BP experienced an approximately 3.5 mm Hg\u2013greater response to chlorthalidone compared with those at an intermediate genetic risk of elevated BP. SBP PRS may also identify individuals with HTN harboring a higher risk of treatment-resistant HTN. Overall, SBP PRS demonstrates potential to identify those who may have greater benefit from chlorthalidone, but future research is needed to determine if PRS can inform initiation and choice of treatment among individuals with HTN.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.3649","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:32:01Z","timestamp":1729697521000},"page":"1134","source":"Crossref","is-referenced-by-count":14,"title":["Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response"],"prefix":"10.1001","volume":"9","author":[{"given":"Nicole D.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Srinivasasainagendra","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Patki","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana C.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhu","family":"Parcha","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Pampana","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Broeckel","sequence":"additional","affiliation":[{"name":"Section of Genomic Pediatrics, Children\u2019s Research Institute, Department of Pediatrics, The Medical College of Wisconsin, Milwaukee"},{"name":"RPRD Diagnostics, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Lange","sequence":"additional","affiliation":[{"name":"Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Arora","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham"},{"name":"Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita A.","family":"Limdi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant K.","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite R.","family":"Irvin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9859","key":"hoi240062r1","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"9455","key":"hoi240062r2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data.","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"issue":"10064","key":"hoi240062r3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants.","volume":"389","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"hoi240062r4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1161\/01.HYP.0000217521.79447.9a","article-title":"Emergence of novel genetic effects on blood pressure and hemodynamics in adolescence: the Georgia Cardiovascular Twin Study.","volume":"47","author":"Kupper","year":"2006","journal-title":"Hypertension"},{"issue":"4","key":"hoi240062r5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41569-020-00466-4","article-title":"Genomics of hypertension: the road to precision medicine.","volume":"18","author":"Padmanabhan","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"hoi240062r6","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.","volume":"50","author":"Evangelou","year":"2018","journal-title":"Nat Genetics"},{"issue":"3","key":"hoi240062r7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/ng.3768","article-title":"Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk.","volume":"49","author":"Warren","year":"2017","journal-title":"Nat Genetics"},{"issue":"1","key":"hoi240062r8","doi-asserted-by":"publisher","first-page":"11940","DOI":"10.1038\/s41598-020-68878-3","article-title":"Human essential hypertension: no significant association of polygenic risk scores with antihypertensive drug responses.","volume":"10","author":"S\u00e1nez T\u00e4htisalo","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"hoi240062r9","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41596-020-0353-1","article-title":"Tutorial: a guide to performing polygenic risk score analyses.","volume":"15","author":"Choi","year":"2020","journal-title":"Nat Protocols"},{"issue":"6","key":"hoi240062r10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003946","article-title":"Association of a multiancestry genome-wide blood pressure polygenic risk score with adverse cardiovascular events.","volume":"15","author":"Parcha","year":"2022","journal-title":"Circ Genomic Precision Med"},{"issue":"1","key":"hoi240062r11","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41467-023-38990-9","article-title":"Evaluating the use of blood pressure polygenic risk scores across race\/ethnic background groups.","volume":"14","author":"Kurniansyah","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"hoi240062r12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40246-021-00339-y","article-title":"Implementation and implications for polygenic risk scores in healthcare.","volume":"15","author":"Slunecka","year":"2021","journal-title":"Hum Genomics"},{"issue":"15","key":"hoi240062r13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.109.914820","article-title":"Pharmacogenomics: the genetics of variable drug responses.","volume":"123","author":"Roden","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"hoi240062r14","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association.","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"hoi240062r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xhgg.2020.100017","article-title":"Inclusion of variants discovered from diverse populations improves polygenic risk score transferability.","volume":"2","author":"Cavazos","year":"2021","journal-title":"HGG Adv"},{"issue":"4, pt 1","key":"hoi240062r16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","article-title":"Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"9","author":"Davis","year":"1996","journal-title":"Am J Hypertens"},{"issue":"23","key":"hoi240062r17","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"hoi240062r18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj.tpj.6500113","article-title":"Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.","volume":"2","author":"Arnett","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"hoi240062r19","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.781451","article-title":"Genetic contributors of incident stroke in 10,700 African Americans with hypertension: a meta-analysis from the genetics of hypertension associated treatments and Reasons for Geographic and Racial Differences in Stroke Studies.","author":"Armstrong","journal-title":"Frontiers Genetics"},{"issue":"7","key":"hoi240062r20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/genes13071260","article-title":"Genetic contributors of efficacy and adverse metabolic effects of chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.","volume":"13","author":"Armstrong","year":"2022","journal-title":"Genes (Basel)"},{"issue":"9","key":"hoi240062r21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/jhh.2015.121","article-title":"The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study.","volume":"30","author":"Do","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"5","key":"hoi240062r22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41588-022-01054-7","article-title":"Improving polygenic prediction in ancestrally diverse populations.","volume":"54","author":"Ruan","year":"2022","journal-title":"Nat Genetics"},{"issue":"4","key":"hoi240062r23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","article-title":"The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation.","volume":"53","author":"Lambert","year":"2021","journal-title":"Nat Genetics"},{"key":"hoi240062r24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets.","volume":"4","author":"Chang","year":"2015","journal-title":"Gigascience"},{"issue":"2","key":"hoi240062r25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamacardio.2022.4466","article-title":"Predictive utility of a coronary artery disease polygenic risk score in primary prevention.","volume":"8","author":"Marston","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"12","key":"hoi240062r26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/jhg.2015.110","article-title":"Evaluation of a two-step iterative resampling procedure for internal validation of genome-wide association studies.","volume":"60","author":"Kang","year":"2015","journal-title":"J Hum Genetics"},{"issue":"3","key":"hoi240062r27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000086678","article-title":"The reasons for geographic and racial differences in stroke study: objectives and design.","volume":"25","author":"Howard","year":"2005","journal-title":"Neuroepidemiology"},{"issue":"8","key":"hoi240062r28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies.","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genetics"},{"issue":"4","key":"hoi240062r29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1161\/HYPERTENSIONAHA.120.16471","article-title":"Polygenic risk scores predict hypertension onset and cardiovascular risk.","volume":"77","author":"Vaura","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"hoi240062r30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/jch.12702","article-title":"Prediction of blood pressure and blood pressure change with a genetic risk score.","volume":"18","author":"Niiranen","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"hoi240062r31","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41467-022-31080-2","article-title":"A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood.","volume":"13","author":"Kurniansyah","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"hoi240062r32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1161\/HYPERTENSIONAHA.111.00649","article-title":"A blood pressure genetic risk score is a significant predictor of incident cardiovascular events in 32,669 individuals.","volume":"61","author":"Havulinna","year":"2013","journal-title":"Hypertension"},{"issue":"11","key":"hoi240062r33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/jamacardio.2022.3191","article-title":"Measured blood pressure, genetically predicted blood pressure, and cardiovascular disease risk in the UK Biobank.","volume":"7","author":"Cho","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"3","key":"hoi240062r34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003554","article-title":"Blood pressure polygenic scores are associated with apparent treatment-resistant hypertension.","volume":"15","author":"Breeyear","year":"2022","journal-title":"Circ Genomic Precision Med"},{"issue":"5","key":"hoi240062r35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"James","year":"2014","journal-title":"JAMA"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2824907\/jamacardiology_armstrong_2024_oi_240062_1733417043.78079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:32:22Z","timestamp":1733949142000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2824907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.3649","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}